Seeking Alpha

Vanda Pharmaceuticals (VNDA) says that additional data from Phase III trials of the company's...

Vanda Pharmaceuticals (VNDA) says that additional data from Phase III trials of the company's Tasimelteon treatment for Non-24-Hour Disorder "clearly demonstrate" that the medicine can train patients' master body clocks to the 24-hour day and that "continued treatment is necessary to maintain entrainment." Non-24-Hour Disorder affects most totally blind people. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector